Colgate-Palmolive Company
CL
$94.04
-3.44%
Colgate-Palmolive is a 220-year-old global consumer staples manufacturer whose portfolio spans oral care (Colgate toothpaste and toothbrushes, more than 40% of sales), personal care (Palmolive soaps, shampoos, deodorants), home care, and the Hill's Pet Nutrition specialty pet food business, which contributes roughly a quarter of revenue and is sold largely through veterinarians and specialty retailers. The company is a textbook category leader rather than a disruptor: it holds dominant global share in manual oral care, operates in over 200 countries, and derives approximately 70% of sales internationally, with nearly half of that from faster-growing emerging markets, giving it a defensive, brand-moat profile distinct from pure-play US staples peers. The current investor debate centers on whether Colgate can sustain the mid-single-digit organic growth and gross-margin expansion it has delivered through 2026 — Q2 revenue rose 4.9% year over year to $5.36 billion with gross margin above 61% — while navigating a rotation narrative that has favored laggard value names over prior leaders, a dynamic highlighted in recent commentary on the growth-to-value rotation. With a 2.85% dividend yield, a beta of just 0.32, and a valuation that has re-rated upward to roughly 30x trailing earnings, the stock sits at the intersection of a safe-haven bid and a debate over whether defensive staples deserve premium multiples in a market rotating toward value.…
CL
Colgate-Palmolive Company
$94.04
Investment Opinion: Should I buy CL Today?
Rating: Hold. Colgate is a high-quality defensive compounder with a dominant oral care franchise, consistent ~5% revenue growth, and a 6% free cash flow yield, but at 29.93x trailing earnings it trades near the top of its historical valuation range and offers only 4.2% upside to the $98.10 average analyst target. The consensus rating is 'buy' (mean 2.05), yet the risk/reward is balanced after the recent 8.15% one-month rally.
Supporting evidence includes Q2 2026 revenue growth of 4.91% year over year, gross margin expansion to 61.48% from 60.06%, a 12.93% net margin, and TTM free cash flow of $3.858 billion (6.0% FCF yield). The 2.85% dividend yield and 0.32 beta make it a portfolio stabilizer, and the forward PE of 23.03x is closer to fair value than the trailing multiple suggests. However, the implied ~30% EPS growth needed to justify the trailing-to-forward gap is aggressive for a staples company.
Key risks include valuation compression toward the 25x midpoint (implying ~16% downside), elevated debt-to-equity of 158.4%, and a thin current ratio of 0.833. The rating would upgrade to Buy if the stock pulls back toward the $87 analyst low target (forward PE ~18x) or if organic growth accelerates above 6%. It would downgrade to Sell if gross margins fall below 59% or if revenue growth decelerates below 3%. Relative to its own history and peers, CL is fairly valued to slightly overvalued, pricing in stability rather than growth.
Sign up to view all
CL 12-Month Price Forecast
Colgate is a high-quality defensive name with a strong brand moat, consistent mid-single-digit growth, and robust cash flow, but the valuation already reflects these strengths. The stock's 20.5% one-year gain and 8.15% one-month rally have pushed it to within 5.5% of its 52-week high, leaving limited near-term upside to the $98.10 average target. The key debate is whether the market's implied ~30% EPS growth is achievable; if it is, the premium is justified, but any disappointment could trigger a de-rating. We would upgrade to bullish if organic growth accelerates above 6% or if the stock pulls back to the $87-$90 range, and downgrade to bearish if gross margins fall below 59% or if a rotation away from staples intensifies.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.15 and implied upside of +4.4% versus the current price.
Average Target
$98.15
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
Coverage is deep and constructive: 20 analysts follow Colgate with a consensus recommendation of "buy" (mean rating 2.05 on a scale where lower is more bullish), an average target price of $98.10, implying +4.2% upside from the current $94.11. The distribution skews positive — recent actions from Piper Sandler (Overweight), RBC (Outperform), JP Morgan (Overweight), UBS (Buy), and Evercore ISI (Outperform) are all reaffirmations of bullish stances, with only TD Cowen (Hold) and Barclays (Equal Weight) sitting on the sidelines — so the consensus leans moderately bullish, though the modest implied upside suggests much of the good news is already in the price after the recent 8% one-month run.
The target range of $87.00 to $110.00 is moderately wide (roughly 26% from low to high), signaling meaningful dispersion in assumptions: the $110 high target requires either multiple expansion toward the mid-30s PE or an acceleration in organic growth and Hill's momentum beyond the current ~5% pace, while the $87 low target essentially prices in a de-rating toward the low end of the historical PE band and margin compression from input costs or FX headwinds. Notably, the current price of $94.11 already sits above the low target, meaning the most bearish analyst sees downside of about 7.6%, and the fact that all ten recent institutional actions were reaffirmations rather than upgrades or downgrades points to stable conviction rather than a shifting narrative. Consensus revenue of $24.19 billion and EPS of $4.78 for the forward period are consistent with the mid-single-digit growth and margin trajectory visible in the quarterly data, making the average target a reasonable base case rather than a stretch.
Bulls vs Bears: CL Investment Factors
The bull case rests on Colgate's unmatched brand moat, consistent ~5% revenue growth, 61%+ gross margins, and a 6% FCF yield, all wrapped in a 0.32-beta defensive package that has outperformed the S&P by 9.2 points year to date. The bear case centers on valuation: at 29.9x trailing earnings near the top of its historical range, the stock already discounts optimistic EPS normalization and margin expansion, leaving limited upside to the $98.10 average target. The single most important tension is whether the market's implied ~30% EPS growth materializes; if it does, the premium is justified, but any shortfall could trigger a de-rating toward the 25x midpoint, implying ~16% downside. Currently, the evidence slightly favors the bear side on valuation grounds, though the bull case on quality and stability remains intact.
Bullish
- Dominant global oral care franchise: Colgate toothpaste and toothbrushes account for more than 40% of sales and the company holds leading global share in manual oral care across 200+ countries. This brand moat supports pricing power, evidenced by gross margin expansion of roughly 140 basis points year over year to 61.48% in Q2 2026.
- Consistent mid-single-digit revenue growth: Q2 2026 revenue rose 4.91% year over year to $5.361 billion, following a steady cadence from $5.110 billion in Q2 2025. This is at the upper end of large-cap staples peers and demonstrates reliable inflation-passing ability.
- Strong free cash flow and shareholder returns: TTM free cash flow is $3.858 billion, a 6.0% FCF yield on the $63.9 billion market cap. Q2 operating cash flow of $995 million comfortably funded $128 million capex, $462 million dividends, and $291 million buybacks.
- Low beta defensive stabilizer: Beta of 0.322 means Colgate moves roughly one-third as much as the S&P 500, offering portfolio downside protection. The stock has outperformed SPY by 9.21 percentage points year to date with only a 17.48% maximum drawdown.
Bearish
- Premium valuation leaves little room: At 29.93x trailing PE, CL trades near the top of its historical 21x-30x band and at a premium to the household products industry's low-to-mid 20s. A de-rating to the 25x midpoint would imply roughly 16% downside even with flat earnings.
- Aggressive implied EPS growth assumption: The 6.9-turn gap between trailing (29.93x) and forward (23.03x) PE implies the market expects roughly 30% EPS growth over the next twelve months. That is an aggressive assumption for a staples company growing revenue at ~5%.
- Elevated leverage and thin liquidity: Debt-to-equity is 158.4% and the current ratio is only 0.833, leaving limited balance-sheet slack. The dividend payout ratio of 85.5% leaves little room for error if earnings disappoint.
- Earnings volatility from non-operating items: Q4 2025 swung to a net loss of $37 million (EPS -$0.046) due to a $970 million other-expense item, distorting trailing metrics including a negative PEG ratio of -1.19. This highlights sensitivity to one-off charges.
CL Technical Analysis
Colgate is in a sustained, orderly uptrend: the stock is up 20.53% over the past year and 21.14% year to date, and at $94.11 it sits at roughly 78.9% of its 52-week range of $74.55 to $99.33. That positioning — high in the range but not pinned to the high — is characteristic of a healthy trend rather than an overextended blow-off top, and the 17.48% maximum drawdown over the period confirms the pullbacks have been shallow and well contained. The stock has essentially recovered the entire September pullback and is now within about 5.5% of its 52-week high, meaning momentum buyers still have room before resistance becomes binding.
Short-term momentum has re-accelerated sharply and is now leading the longer-term trend: the 1-month change of +8.15% dwarfs the 3-month change of just +1.22%, a pattern that tells us the stock consolidated through July and August (peaking near $95 in early July before fading to the mid-$80s by late September) and has since broken out again, with the last three sessions printing $92.78, $92.67, and $94.11 on rising conviction. Relative strength confirms the move is stock-specific rather than beta-driven: CL has outperformed SPY by 6.93 percentage points over one month and 9.21 points year to date, though it lagged by 1.47 points over three months, consistent with a mid-summer stall that has now been resolved to the upside. Volume of roughly 5.78 million shares on the latest session is unremarkable but adequate, and the absence of a sharp volume spike suggests accumulation rather than a speculative squeeze.
Key technical levels are clean: support sits at the 52-week low of $74.55, with a nearer intermediate floor around the $84-$85 zone where the stock based in late September and early October, while resistance is the 52-week high of $99.33 — a breakout above which would open a new leg higher and likely force momentum and trend-following funds to add exposure. A breakdown below $84 would break the sequence of higher lows and flag a failed breakout, putting the $74.55 low back in play. The critical risk-management input is beta of 0.322, meaning Colgate moves roughly one-third as much as the S&P 500 — this low volatility is a portfolio stabilizer but also means the 20.5% one-year gain was achieved with very little market help, and position sizing should reflect that the stock's low beta offers limited downside cushion if a staples-specific de-rating occurs.
Beta
0.32
0.32x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+19.9%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +9.4% | -1.0% |
| 3m | +3.6% | +2.9% |
| 6m | +11.1% | +6.5% |
| 1y | +19.9% | +13.1% |
| ytd | +21.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue is growing steadily rather than spectacularly: Q2 2026 revenue of $5.361 billion rose 4.91% year over year from $5.110 billion in Q2 2025, and the sequential cadence of $5.324 billion (Q1 2026), $5.361 billion (Q2 2026) versus $5.230 billion (Q4 2025) and $5.131 billion (Q3 2025) shows a consistent low-to-mid-single-digit trajectory with no acceleration or deceleration inflection. Segment data shows the core Oral, Personal and Home Care business at $4.166 billion and Hill's Pet Nutrition at $1.195 billion, meaning the pet franchise is roughly 22% of quarterly sales and, given its premium positioning and vet-channel distribution, is likely the higher-growth, higher-margin contributor supporting the overall mix. For a defensive staples compounder, ~5% top-line growth is at the upper end of the peer group and supports the investment case as a reliable, inflation-passing franchise rather than a growth story.
Profitability is robust and margins are expanding: Q2 2026 net income was $693 million on a 12.93% net margin, with gross margin of 61.48% (up from 60.06% in Q2 2025 and 59.42% in Q3 2025), operating margin of 18.95%, and EBITDA of $1.167 billion at a 21.77% EBITDA margin. The one blemish is Q4 2025, when a $970 million swing in other income/expenses drove a net loss of $37 million and a negative 0.71% net margin — an anomaly that has fully reversed in the two subsequent quarters, with Q1 2026 net income of $646 million and Q2's $693 million. At 60%+ gross margin and high-teens operating margin, Colgate sits comfortably in line with, or slightly above, typical household products industry economics, and the year-over-year gross margin expansion of roughly 140 basis points is the clearest evidence that pricing and productivity are outrunning input costs.
Balance sheet and cash flow present a mixed but manageable picture: free cash flow TTM is a strong $3.858 billion against a $63.9 billion market cap (about 6.0% FCF yield), and Q2 2026 operating cash flow of $995 million comfortably funded $128 million of capex, $462 million of dividends, and $291 million of buybacks. However, debt-to-equity is elevated at 158.4%, the current ratio is a thin 0.833, and ROE of 39.48% is flattered by a very small equity base (reflected in a price-to-book of 1,183x) rather than by exceptional returns on assets, which are a more modest 15.84%. The company generates more than enough cash to self-fund growth and shareholder returns, but the low current ratio and high leverage mean it has limited balance-sheet slack — financial risk is low given the stability of staples cash flows, but the dividend payout ratio of 85.5% leaves little room for error if earnings disappoint.
Quarterly Revenue
$5.4B
2026-06
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
61.5%
Latest Quarter
Free Cash Flow
$3.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Because Colgate is solidly profitable — Q2 2026 net income of $693 million and trailing EPS positive — the PE ratio is the appropriate primary metric, and it currently reads 29.93x trailing versus 23.03x forward. The 6.9-turn gap between trailing and forward multiples implies the market expects roughly 30% EPS growth over the next twelve months, consistent with consensus estimated EPS of $4.78 versus the depressed trailing figure distorted by the Q4 2025 loss; that is an aggressive implied growth rate for a staples company and is the single most important valuation assumption to stress-test.
On a peer basis, Colgate's 29.9x trailing PE and 3.14x PS sit at a premium to the household and personal products industry, where large-cap staples typically trade in the low-to-mid 20s on earnings; the 23.0x forward PE is closer to fair value but still above the sector, and the 14.6x EV/EBITDA and 3.83x EV/Sales confirm a premium positioning. The premium is defensible on quality grounds — 61% gross margins, a dominant global oral care franchise, and a 2.85% dividend yield with a 0.32 beta — but it is not obviously justified by growth, since 4.9% revenue growth is only in line with peers, meaning investors are paying for stability and brand moat rather than acceleration. The negative PEG ratio of -1.19 is a mechanical artifact of the trailing earnings distortion and should be disregarded.
Historically, Colgate's own PE band has ranged from roughly 21x to 30x over the past several years, with the 26.3x reading in Q2 2026 and the current 29.9x trailing multiple placing the stock near the top of its own range; the PS ratio of 3.14x, however, is well below the 12-16x quarterly PS readings in the historical ratios file, a discrepancy that reflects differing share-count and market-cap conventions in that dataset rather than a genuine valuation collapse. The more reliable signal is the PE: at ~30x trailing, the market is pricing in optimistic normalization of earnings and continued margin expansion, leaving limited room for disappointment — a de-rating toward the 25x midpoint of the historical band would imply roughly 16% downside even with flat earnings.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but manageable. Debt-to-equity of 158.4% and a current ratio of 0.833 indicate limited balance-sheet flexibility, while the 85.5% dividend payout ratio leaves little cushion if earnings decline. The Q4 2025 net loss of $37 million from a $970 million other-expense swing demonstrates earnings volatility from non-operating items, and the 4.9% revenue growth is dependent on continued pricing power and volume stability in emerging markets, which contribute nearly half of international sales. Free cash flow of $3.858 billion provides a strong buffer, but the company's ability to sustain both dividends and buybacks could be tested in a downturn.
Market and competitive risks center on valuation compression. At 29.93x trailing PE, CL trades at a premium to the household products industry's low-to-mid 20s and near the top of its own 21x-30x historical band. A rotation from defensive leaders to value laggards, as highlighted in recent commentary, could pressure the multiple; the stock's 3-month relative strength versus SPY is already -1.47%. Beta of 0.322 limits market-correlation risk, but a staples-specific de-rating would not be cushioned by low beta. Competitive threats in oral care and pet nutrition, plus FX headwinds from ~70% international sales, add to the external risk profile.
The worst-case scenario involves a combination of slowing organic growth, margin compression from input costs, and a valuation de-rating. If EPS growth disappoints and the PE compresses to the 25x midpoint of its historical range, the stock could fall roughly 16% from $94.11 to about $79, near the 52-week low of $74.55 (a 20.8% decline). The analyst low target of $87 implies a more modest 7.6% downside, but a broader market rotation could push shares toward the 52-week low, representing a potential loss of approximately 21% from current levels.
FAQ
The most severe risk is valuation compression: at 29.93x trailing PE, a rotation away from defensive staples could push the multiple toward 25x, implying ~16% downside. Financial risk is moderate, with debt-to-equity of 158.4% and a current ratio of 0.833 limiting balance-sheet flexibility, while the 85.5% dividend payout ratio leaves little room for error. Competitive and macro risks include FX headwinds from ~70% international sales and potential market-share pressure in oral care. Company-specific risk includes earnings volatility, as shown by the Q4 2025 net loss of $37 million from a $970 million other-expense swing. Ranked by severity: valuation compression, financial leverage, FX/macro, and earnings volatility.
Our 12-month forecast has a base case (55% probability) of $95-$100, aligned with the $98.10 analyst average target, assuming mid-single-digit revenue growth and EPS near $4.78. The bull case (25% probability) targets $105-$110, requiring organic growth above 6% and multiple expansion toward the mid-30s PE. The bear case (20% probability) targets $75-$87, reflecting a de-rating to 25x or below and slower growth, with the 52-week low of $74.55 as the downside anchor. The most likely scenario is the base case, hinging on whether the market's implied ~30% EPS growth materializes; any shortfall could shift the outcome toward the bear case.
CL appears fairly valued to slightly overvalued. Its trailing PE of 29.93x sits near the top of its historical 21x-30x band and at a premium to the household products industry's low-to-mid 20s. The forward PE of 23.03x is closer to fair value but still above peers, while the EV/EBITDA of 14.62x and PS of 3.14x confirm a premium positioning. The market is paying for stability, brand moat, and a 2.85% dividend yield rather than growth, since 4.9% revenue growth is only in line with peers. A de-rating to the 25x midpoint would imply roughly 16% downside, suggesting the current price already discounts optimistic EPS growth.
From a risk/reward perspective, CL offers limited upside at current levels: the average analyst target of $98.10 implies just 4.2% upside, and the stock trades at 29.93x trailing earnings, near the top of its historical range. The biggest downside risk is a valuation de-rating toward the 25x midpoint, which would imply roughly 16% downside even with flat earnings. However, the stock's 0.32 beta, 2.85% dividend yield, and consistent ~5% revenue growth make it a solid defensive holding for risk-averse investors. It is a good buy for long-term income-focused portfolios, especially on pullbacks toward the $87-$90 range, but less attractive for investors seeking near-term capital appreciation.
CL is best suited for long-term investment, given its low beta of 0.322, stable ~5% revenue growth, and 2.85% dividend yield. The stock's 17.48% maximum drawdown and orderly uptrend make it a low-volatility portfolio stabilizer, but its 29.93x trailing PE limits near-term upside, making it less attractive for short-term trading. Earnings visibility is high, with 20 analysts covering the stock and a consensus buy rating, supporting a buy-and-hold approach. A suggested minimum holding period is 2-3 years to capture dividend compounding and potential multiple normalization. Short-term traders should watch the $99.33 resistance and $84 support levels for entry and exit points.